Investigators in the ACTIVE trial previously found that that the
drug reduces fractures and increases bone mineral density in
postmenopausal women with osteoporosis. This latest analysis, which is
published in the
(published
by the American Society for Bone and Mineral Research), evaluated
whether these benefits were consistent across different levels of
baseline risk.
‘Abaloparatide-SC provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.’
"The landmark ACTIVE trial results show that abaloparatide-SC may
provide substantial benefit for a broad range of postmenopausal women
with osteoporosis," said lead author Dr. Felicia Cosman. "Anabolic therapy
could provide more consistent potent and early benefits to patients and
may be the most efficient way to achieve ultimate bone mineral density
goals."
Source: Eurekalert
